SCHEMBL30315381

SCHEMBL30315381

CC(C)n1cnc2c(NCCNc3ccccn3)nc(-c3csc4ccccc34)nc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.70
▸ CDK5 Q00535 14/20 0.47
▸ CDK5R1 Q15078 12/20 0.47
▸ CDK2 P24941 9/20 0.47
▸ DYRK1A Q13627 6/20 0.47
▸ CCNA2 P20248 5/20 0.47
▸ CCNA1 P78396 5/20 0.47
▸ CDK1 P06493 13/20 0.42
▸ CCNB1 P14635 10/20 0.42
▸ CCNB2 O95067 7/20 0.42
▸ CCNB3 Q8WWL7 7/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ CDK4 P11802 3/20 0.40
▸ CCND1 P24385 3/20 0.40
▸ CCNE1 P24864 3/20 0.40
▸ MAPK1 P28482 3/20 0.40
▸ CDK7 P50613 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2314146 1.00 AHR (0.70) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL15011335 0.85 AHR (0.87) AHRCDK5CDK2DYRK1ACCNA2
SCHEMBL2313531 0.84 AHR (0.71) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL30315451 0.84 AHR (0.71) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL24689885 0.83 AHR (0.72) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL2318576 0.83 AHR (0.69) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL19766270 0.83 AHR (0.85) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL2317306 0.83 AHR (0.85) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL29686381 0.82 AHR (1.00) AHRCDK5CDK5R1CDK2DYRK1A
SCHEMBL2314090 0.82 AHR (0.79) AHRCDK5CDK5R1CDK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3524604-B1 EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE NOVARTIS AG (CH) 2023-03-29 — — EP disclosed
Send feedback